What is Zacks Research’s Estimate for Amgen Q4 Earnings?

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at Zacks Research reduced their Q4 2024 EPS estimates for Amgen in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $4.86 for the quarter, down from their previous estimate of $5.40. The consensus estimate for Amgen’s current full-year earnings is $19.52 per share. Zacks Research also issued estimates for Amgen’s Q3 2025 earnings at $5.22 EPS and Q3 2026 earnings at $5.44 EPS.

Other equities analysts also recently issued research reports about the stock. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Citigroup assumed coverage on Amgen in a research report on Thursday, November 14th. They set a “neutral” rating and a $335.00 target price for the company. Jefferies Financial Group restated a “buy” rating and issued a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Bank of America increased their target price on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Stock Down 0.2 %

Shares of AMGN opened at $294.00 on Monday. Amgen has a 12-month low of $260.68 and a 12-month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market capitalization of $158.03 billion, a PE ratio of 37.64, a price-to-earnings-growth ratio of 2.63 and a beta of 0.60. The business’s 50 day moving average is $315.69 and its 200 day moving average is $318.05.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. During the same quarter in the previous year, the company posted $4.96 earnings per share. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis.

Institutional Trading of Amgen

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Keynote Financial Services LLC grew its stake in Amgen by 0.6% in the second quarter. Keynote Financial Services LLC now owns 4,898 shares of the medical research company’s stock worth $1,530,000 after purchasing an additional 30 shares in the last quarter. Ascent Group LLC increased its holdings in shares of Amgen by 0.3% in the 2nd quarter. Ascent Group LLC now owns 10,949 shares of the medical research company’s stock worth $3,421,000 after acquiring an additional 31 shares during the period. Hofer & Associates. Inc increased its stake in shares of Amgen by 0.5% in the second quarter. Hofer & Associates. Inc now owns 6,477 shares of the medical research company’s stock valued at $2,024,000 after purchasing an additional 32 shares during the period. Cadinha & Co. LLC raised its stake in Amgen by 0.6% during the 3rd quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company’s stock valued at $1,678,000 after acquiring an additional 32 shares in the last quarter. Finally, Lansing Street Advisors raised its stake in shares of Amgen by 1.3% during the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company’s stock valued at $832,000 after purchasing an additional 32 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.